| 22.26 1.18 (5.6%) | 08-11 12:42 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 29.05  |
1-year : | 33.94 |
| Resists | First : | 24.87 |
Second : | 29.05 |
| Pivot price | 20.89  |
|||
| Supports | First : | 21.6 |
Second : | 19.57 |
| MAs | MA(5) : | 20.89 |
MA(20) : | 21.09 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -0.5 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 32.9 |
D(3) : | 22.9 |
| RSI | RSI(14): 55.1 |
|||
| 52-week | High : | 27 | Low : | 19.57 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ KARD ] has closed below upper band by 7.6%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 21.85 - 21.94 | 21.94 - 22.02 |
| Low: | 20.1 - 20.2 | 20.2 - 20.29 |
| Close: | 20.92 - 21.07 | 21.07 - 21.22 |
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
Tue, 11 Aug 2026
Kardigan, Inc. 2Q 2026: Net loss $116.2M, EPS $(4.61) — 10-Q Summary - TradingView
Tue, 11 Aug 2026
Kardigan: Q2 Earnings Snapshot - kens5.com
Tue, 11 Aug 2026
Kardigan, Inc. (NASDAQ:KARD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Tue, 11 Aug 2026
Kardigan reports Q2 2026 net loss $116.2M, cash $660.7M after IPO - TradingView
Thu, 02 Jul 2026
What is the current Price Target and Forecast for KARDIGAN INC (KARD) - Zacks Investment Research
Mon, 22 Jun 2026
Kardigan closes $460 million IPO on Nasdaq - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 89 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 34.9 (%) |
| Held by Institutions | 40.8 (%) |
| Shares Short | 1,470 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -18.14 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -186 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -8.67 |
| PEG Ratio | 0 |
| Price to Book value | -1.23 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|